Meet Dr. Cohn
Susan L. Cohn, MD, is a highly respected expert in pediatric cancers and blood diseases. She is a leading authority on neuroblastoma, a cancer of nerve cells and the most common type of cancer found in infants.
Dr. Cohn is actively researching several aspects of neuroblastoma. She leads clinical trials for children with newly diagnosed neuroblastoma and is also one of the few pediatric oncologists in the United States who is conducting Phase I clinical trials of promising treatments for patients with relapsed disease. Her team has established the only 131I-meta-iodobenzlyguanidine (MIBG) treatment program in Illinois. She also is conducting research in the laboratory focused on developing more effective treatments for children with this aggressive cancer.
Dr. Cohn’s research has received generous support from the National Institutes of Health/National Cancer Institute, the National Institute of Neurological Disorders and Stroke, the St. Baldrick’s Foundation, and Alex’s Lemonade Stand Foundation.
Dr. Cohn has held several leadership positions in national pediatric cooperative clinical research groups, including serving as the first chair of the Children's Oncology Group (COG) Neuroblastoma Disease Committee. She is the co-Chair of the International Neuroblastoma Risk Group (INRG) Task Force, and a past member of the Board of Directors for the American Society of Clinical Oncology (ASCO) and was ASCO Treasurer from 2012-2015. She currently serves on ASCO’s Conquer Cancer Foundation Board of Directors and the St. Baldrick’s Foundation Board of Directors. In 2016, she received the American Society of Clinical Oncology (ASCO) Pediatric Oncology Award, and in 2019, she received the American Association of Cancer Research (AACR) Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research.
A prolific author, Dr. Cohn has published more than 200 peer-reviewed journal articles, several book chapters, and has co-edited two books. She also serves on the editorial boards for the Journal of Clinical Oncology and Pediatric Blood and Cancer.
Dr. Cohn has been selected as a top doctor by Chicago magazine and Top Cancer Doctor by Newsweek and Castle Connolly.
Areas of Expertise
- Pediatric Oncology
- Solid Tumors in Children
- Pediatric Hematology
- Neuroblastoma
Board Certifications
- Pediatric Hematology and Oncology
- Pediatrics
Memberships & Medical Societies
- American Association for Cancer Research
- American Academy of Pediatrics
- American Society of Pediatric Hematology/Oncology
- American Society of Clinical Oncology
- Society for Pediatric Research
Practicing Since
- 1987
Languages Spoken
- English
Medical Education
- University of Illinois College of Medicine
Residency
- Michael Reese Hospital
Fellowship
- Ann and Robert H. Lurie Children's Hospital
News & Research
View Published Papers- Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma
- Collecting and Storing Biological Samples From Patients With Ewing Sarcoma
- Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
- Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
- Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
- Study of Kidney Tumors in Younger Patients
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
- Enrollment on the Childhood Cancer Research Network (CCRN) of the Children s Oncology Group
- Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
- Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
- Expanded Access Protocol Using 131I-MIBG
- Project: Every Child for Younger Patients With Cancer
- Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
- Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
- Aetna HMO (specialists only)
- Aetna POS
- Aetna PPO
- BCBS Blue Precision HMO (specialists only)
- BCBS HMO (HMOI) (specialists only)
- BCBS PPO
- Cigna HMO
- Cigna POS
- Cigna PPO
- CountyCare *see insurance page
- Aetna Better Health *see insurance page
- Medicare
- Multiplan PPO
- PHCS PPO
- United Choice Plus POS/PPO
- United Options (PPO)
- United Select (HMO & EPO) (specialists only)
- United W500 Emergent Wrap
- Aetna Medicare Advantage HMO & PPO
- BCBS Medicare Advantage HMO & PPO
- Humana Medicare Advantage Choice PPO
- Humana Medicare Advantage Gold Choice PFFS
- Humana Medicare Advantage Gold Plus HMO
- United Choice HMO (specialists only)
- University of Chicago Health Plan (UCHP)
Our list of accepted insurance providers is subject to change at any time. You should contact your insurance company to confirm UChicago Medicine participates in their network before scheduling your appointment. If your insurance company is not listed here, or if you have any other questions, please contact Managed.Care@uchospitals.edu.
Comer Children's Hospital - Hyde Park
Request an Appointment at Comer Children's Hospital - Hyde Park
To Refer a Patient
Refer a PatientSusan Cohn, MD: An unwavering dedication to helping children with neuroblastoma
A leading authority on neuroblastoma, Susan Cohn, MD, is on a relentless drive to advance the treatment for and care of children with this rare pediatric cancer.
